Alirocumab, efficacy and safety in reducing lipids and cardiovascular events


Alirocumab ( Praluent ), a monoclonal antibody that inhibits proprotein convertase subtilisin – kexin type 9 ( PCSK9 ), has been shown to reduce low-density lipoprotein ( LDL ) cholesterol levels in patients who are receiving statin therapy.
Larger and longer-term studies are needed to establish safety and efficacy.

Researchers have conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter ( 1.8 mmol per liter ) or more and were receiving treatment with statins at the maximum tolerated dose ( the highest dose associated with an acceptable side-effect profile ), with or without other lipid-lowering therapy.
Patients were randomly assigned in a 2:1 ratio to receive Alirocumab ( 150 mg ) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks.

The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24.

At week 24, the difference between the Alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was −62 percentage points ( P less than 0.001 ); the treatment effect remained consistent over a period of 78 weeks.

The Alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions ( 5.9% vs. 4.2% ), myalgia ( 5.4% vs. 2.9% ), neurocognitive events ( 1.2% vs. 0.5% ), and ophthalmologic events ( 2.9% vs. 1.9% ).

In a post hoc analysis, the rate of major adverse cardiovascular events ( death from coronary heart disease, nonfatal myocardial infarction, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization ) was lower with Alirocumab than with placebo ( 1.7% vs. 3.3%; hazard ratio, HR=0.52; 95% confidence interval, 0.31 to 0.90; nominal P=0.02 ).

In conclusion, over a period of 78 weeks, Alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels.
In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with Alirocumab. ( Xagena )

Robinson JG et al, NEJM 2015; Epub ahead of print

XagenaMedicine_2015



Indietro

Altri articoli

The ODYSSEY OUTCOMES ( Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab ) trial compared...


The European Commission ( EC ) has approved a new indication for Praluent ( Alirocumab ), to reduce cardiovascular (...


The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...


Patients with heterozygous familial hypercholesterolemia ( HeFH ) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled...


In statin trials, men and women have shown similar relative risk reductions in cardiovascular events per 39 mg/dL low-density lipoprotein...


ODYSSEY OLE ( open-label extension ) has included patients diagnosed with heterozygous familial hypercholesterolemia ( HeFH ), receiving maximally tolerated...


Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited...


A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin...


Two anti-proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) monoclonal antibodies, Alirocumab and Evolocumab, have been approved for the treatment...


The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving...